【Abstract】 Objective To investigate the effect of alprostadil combined with adefovir dipivoxil in the treatment of liver cirrhosis and the effect on transforming growth factorβ1 (TGF-β1) and liver function. Methods 298 patients with hepatitis and cirrhosis treated in our hospital from March 2017 to March 2019 were randomly divided into observation group (150 cases) and control group (148 cases). The control group was treated with adefovir dipivoxil, and the observation group was treated with alprostadil on the basis of the control group. The clinical effect, serum TGF-β1, TNF-α, yaluronic acid (HA), procollagen III (PCIII), laminin (LN), total bilirubin (TBIL), albumin (ALB), alanine aminotransferase (AST) and complications of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group (P＜0.05). The serum levels of TGF-β1 and TNF-α in the two groups were significantly improved compared with those before treatment, and the levels of TGF-β1 and TNF-α in the observation group were lower than those in the control group (P＜0.05). The levels of serum HA, PCIII and LN in the two groups were significantly improved compared with those before treatment, and the levels of HA, PCIII and LN in the observation group were lower than those in the control group (P＜0.05). The levels of TBIL, ALB and AST in the two groups were significantly improved compared with those before treatment, and the levels of TBIL, ALB and AST in the observation group were significantly improved compared with those in the control group (P＜0.05). The total incidence of complications in the two groups was significantly higher than that in the control group (P＜0.05). Conclusion The combination of alprostadil and adefovir dipivoxil in patients with hepatitis and cirrhosis is effective in improving the level of serum TGF-β 1 and liver function.